Zanubrutinib is currently in clinical development for treating relapsed or refractory marginal zone lymphoma (MZL). MZL is a rare group of non-Hodgkin’s lymphomas that affect a type of immune cell called B-cells. These MZLs are slow growing and do not always cause symptoms. Broad symptoms that do sometimes appear in MZL patients include unexplained weight loss, night sweats and fever. There are a limited number of treatment options available to MZL patients who are relapsed or refractory to initial treatment, and current treatments often result in adverse side-effects. Therefore, there is a need to develop additional treatment options for these patients.
Zanubrutinib for treating marginal zone lymphoma
![featured image](https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/Patients-Public_Motifs_Conduction-broadcasting_RGB-scaled_edit1233.jpg)
Zanubrutinib is currently in clinical development for treating relapsed or refractory marginal zone lymphoma (MZL). MZL is a rare group of non-Hodgkin’s lymphomas that affect a type of immune cell called B-cells.
Interventions:
Zanubrutinib (BGB-3111; Brukinsa)
Indications:
Marginal zone lymphoma (MZL)
Therapeutic Areas:
Haematological Cancer and Lymphomas
Year:
2022